CEimpact Podcast
The CEimpact Podcast features two shows:
GameChangers Clinical Updates
Precept2Practice
GameChangers Clinical Update Series:
The GameChangers podcast, hosted by Rachel Maynard, PharmD, features the latest game-changing pharmacotherapy advances impacting patient care. New episodes arrive every Monday. Listeners can purchase the episode to earn CE credit at: https://www.ceimpact.com/resources/podcast/
Precept2Practice
The Precept2Practice podcast, hosted by Kathy Schott, brings you tools to mentor students and residents with confidence. New episodes arrive on the third Wednesday of every month. Preceptor By Design™ subscribers can earn CE credit for each episode.
Give us a follow, tune in regularly, and turn your drive time, coffee break, or chart review into a chance to level up your practice. CEimpact continuing education makes pharmacy learning inspiring!
Check back each week for our latest episodes.
CEimpact Podcast
Tirzepatide: A "Twincretin" GameChanger?
Curious about tirzepatide and what it means for patients? Tirzepatide, a combination GLP-1 and GIP agonist, was just approved by the Food and Drug Administration for the treatment of diabetes. Tirzepatide has also gained attention for its weight-reducing effects. However, how does tirzepatide compare to other GLP-1 agonists? Is tirzepaide a GameChanger for type 2 diabetes management? Learn more with host, Geoff Wall.
The GameChanger
Tirzepatide is the first in its class to hit the market and has been shown to be as or more effective than semaglutide in glycemic control and weight reduction.
Show Segments
00:00 – Introductions
01:15 – Type 2 Diabetes & Treatment
02:29 – Glucagon-like peptide-1 (GLP-1) Agonists
03:04 – Glucose-dependent insulinotropic polypeptide (GIP) Agonist
03:55 – Tirzepatide vs Semaglutide
14:27 - Tirzepatide vs Insulin
21:15 – Retinopathy & Financial Considerations
22:30 – Closing Remarks
Host
Geoff Wall, PharmD., BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
References and Resources
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- Once-Weekly Tirzeaptide Versus Once-Daily Insulin Degludec as Add-On to Metformin With or Without SGLT2 Inhibitors in Patients With Type 2 Diabetes (SURPASS-3): A Randomized, Open-Label, Parallel-Group, Phase 3 Trial
- Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
Redeem your CPE or CME here
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
- Pharmacists: Get a membership
- Prescribers: Get a membership
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
- Describe the safety and efficacy of tirzepatide compared to GLP-1 agonists
- Discuss the use of tirzepatide compared to basal insulin for blood glucose control
- Select a patient who may be a candidate for tirzepatide therapy
0.05 CEU/0.5 Hr
UAN: 0107-0000-22-234-H01-P
Initial release date: 06/27/2022
Expiration date: 06/27/2023
Additional CPE and CME details can be found here.